Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 15, Issue 5, Pages 523-536Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2008.12.489
Keywords
Busulfan; Conditioning regimens; Hematologic malignancies; Hematopoietic stem cell transplantation
Categories
Funding
- National Institutes of Health [2PO1 CA55164, 2P30CA16672-26]
- Stephen L. and Lavinia P. Boyd Fund
- NATIONAL CANCER INSTITUTE [P01CA055164, P30CA016672] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside analog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the conditioning chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell transplantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation. Biol Blood Marrow Transplant 15: 523-536 (2009) (c) 2009 American Society for Blood and Marrow Transplantation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available